22 batches of drugs were not qualified in the spot check, and Chinese herbal pieces were also recruited!

[trends of pharmaceutical network industry] in recent years, the market position of Chinese herbal medicine in the pharmaceutical industry has been continuously improved, and the scale of the industry has continued to expand According to some data, the market scale of Chinese Herbal Pieces in 2017 was 216.53 billion yuan, and that in 2018 was about 270 billion yuan However, the market supervision and spot check have become increasingly strict Recently, on December 16, Hainan Province and Hunan Province issued quality announcements The results of sampling showed that traditional Chinese medicine and Chinese herbal pieces are still the focus Of the 22 batches that do not meet the requirements, 21 are Chinese medicinal materials and Chinese herbal pieces In fact, since November, many local drug administrations have issued the notice of unqualified Chinese herbal pieces At present, at least 317 batches of Chinese herbal pieces have been found unqualified On November 26, the State Food and Drug Administration issued the notice of No 85 drug in 2019 that does not meet the requirements It was found that among the 57 batches of unqualified drugs, 11 batches were preparations and 46 batches were pieces of Chinese herbal medicine It is worth noting that these include two OTC, calcium gluconate oral solution and cold cough syrup; three prescription drugs, respectively, acetylcysteine solution for inhalation and eperisone hydrochloride tablets On November 22, Chongqing and Heilongjiang drug regulatory bureaus issued drug quality announcements, among which, Chongqing investigated and dealt with 45 batches of substandard drugs, all of which were Chinese herbal medicines and their pieces, including Atractylodes macrocephala, mulberry leaves, plantain grass, etc.; while Heilongjiang investigated and dealt with 11 batches of drugs, all of which were Chinese herbal medicines and their pieces, including fenvaleria, jujube kernel, Schisandra chinensis, bupleurum, etc On the same day, Hainan Drug Administration issued the notice on the information of drug spot check and inspection in the 11th phase (the 50th phase in total) in 2019, which shows that in October 2019, Hainan Province completed 285 batches of drug spot check, including 278 batches planned to be spot checked, 7 batches supervised to be spot checked, 277 batches inspected to be qualified and 8 batches unqualified Another 6 batches of Chinese herbal pieces were found to be unqualified, and the unqualified items related to properties and sulfur dioxide residue In addition, on November 14, the websites of Hubei and Jiangxi drug administrations also issued new drug quality notices, in which 38 batches of drugs were found to be unqualified in Hubei Province, including 32 batches of Chinese herbal pieces; 269 batches of drugs were found to be unqualified in Jiangxi Province, including 167 batches of Chinese herbal pieces In fact, in recent years, the state has paid more and more attention to the treatment of traditional Chinese medicine As early as 2013, a top-down food and drug safety "defense war" has been launched in the country since the special action of "two strikes and two constructions" was launched Moreover, in August 2018, the State Food and Drug Administration issued the notice on printing and distributing the work plan for the centralized treatment of the quality of Chinese herbal pieces, which made it clear that after a one-year centralized treatment, the supervision of Chinese Herbal Pieces in various regions has been continuously strengthened At present, it seems that under the supervision of governments at all levels and drug regulatory departments, the professional market of traditional Chinese medicine, the production, circulation and use of traditional Chinese medicine pieces and other links have indeed improved significantly and made remarkable progress According to the sampling inspection of the quality of Chinese herbal medicines and pieces of decoction, the qualification rate from 2013 to 2018 keeps rising, from 64% in 2013 to 88% in 2018, and the quality has steadily improved However, due to the lack of resources, the continuous expansion of market demand, long industrial chain and other factors, there are still unqualified quality, counterfeit sales, illegal operation and other phenomena in the traditional Chinese medicine industry, so in the future, the country will continue to strengthen market supervision and management.